What's the Tariff on Pharmaceuticals?
Pharmaceuticals face up to 100% Section 232 tariffs on patented drugs as of July 2026. Lower rates (10-15%) apply to companies with onshoring or pricing agreements.
Current Tariff Rate
100%
Pre-2025 Rate
0%
Rate Increase
+100pp
Price Impact
+100%
+$350
Real-World Price Impact
Before Tariffs
$350
Patented Rx drug (30-day)
After Tariffs
$700
Patented Rx drug (30-day)
That's $350 more per unit — a 100% price increase paid by the American buyer.
Note: Price estimates assume full tariff pass-through to consumers. Actual retail prices may vary — manufacturers may absorb some costs, shift production, or adjust margins.
The Story Behind This Tariff
The pharmaceutical tariff landscape shifted dramatically on July 31, 2026, when Section 232 national security tariffs took effect on imported drugs. Patented medications face a staggering 100% tariff unless their manufacturer has negotiated an onshoring or pricing agreement with the administration. Companies with trade deal partner status pay 10-15%. This creates a two-tier system: Big Pharma companies like Pfizer (Ireland-based manufacturing) and Novartis (Switzerland) that agree to build US production facilities or cut drug prices get preferential rates, while holdouts face tariffs that could double the cost of specialty medications. The tariff affects roughly $97 billion in annual pharmaceutical imports. Generic drugs, heavily sourced from India, face lower rates but are still impacted. The policy has accelerated announcements of new US drug manufacturing plants, though actual production is years away.
📦 Supply Chain
Primary Origin
IN
Made in USA
28%
Import Volume
$195B
Alternatives
Ireland (Pfizer, big pharma), domestic expansion (slow)
📅 Tariff Timeline
2018
Pharmaceuticals excluded from Section 301
0%2020
COVID exposes API supply chain vulnerability
0%2025
Section 122 baseline applied to all pharma imports
10%Jul 31, 2026
Section 232 pharmaceutical tariffs take effect — 100% on patented drugs, 15% baseline for trade deal partners
15–100%👥 Consumer Impact
Households Affected
130M
Annual Cost Per Household
$340
💡 Did You Know?
- •China manufactures 80% of the world's active pharmaceutical ingredients — the raw materials in nearly every pill Americans take
- •India produces 40% of US generic drugs but sources 70% of its own APIs from China, creating a dependency chain
- •The US cannot currently manufacture common antibiotics like amoxicillin domestically — the last US penicillin plant closed in 2004
- •The July 2026 Section 232 pharma tariff is the largest ever applied to medicines — 100% on patented drugs without onshoring agreements
Tariff Details
- HTS Code
- 3004.90
- Current Rate
- 100%
- Pre-2025 Rate
- 0%
- Tariff Type
- Section 232
Legal Authority
Section 232 (National Security)
Effective: Various (2018-2025)
Tariffs on imports deemed a threat to national security
The tariff on Pharmaceuticals is paid by the American importer at the port of entry and passed through to consumers as higher retail prices. The foreign manufacturer does not pay the tariff.
Who Actually Pays This Tariff?
Despite claims that tariffs are paid by foreign countries, the 100% tariff on Pharmaceuticals is paid by American importers — US companies that purchase these goods from abroad. The cost is then passed to American consumers through higher retail prices.
- ✓ The foreign seller receives the same price as before
- ✓ The US importer pays 100% of the customs value to CBP
- ✓ The retailer marks up the higher landed cost
- ✓ You pay more at the register: $350 → $700
Related Products in Industrial
Steel (Hot-Rolled)
25%
1 ton HR coil: $750 → $938
Aluminum (Unwrought)
25%
1 ton aluminum: $2,400 → $3,000
Semiconductors
50%
Chip batch (1000 units): $5,000 → $7,500
Copper Wire
25%
1000 ft copper wire: $350 → $438
Lithium-Ion Batteries
54%
EV battery pack: $8,000 → $12,320
Solar Panels
54%
10 kW system: $15,000 → $23,100
🔍 Dig Deeper
See the Full Picture
Tariffs affect thousands of products. See how much they're costing your household.